eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

Interview with Professor Janusz Skowronek
ABS 2015
vol. 10
Original paper

Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease

Jörg S Zimmermann, Rudolf Osieka, Thorsten Bruns, Helge Hollberg, Bastian Wiechmann, Olaf Netzbandt, Jörg Sablotny, Michael Malade, Matthias Heitz, Fritz Bernhardt, Jörg Tiemann, Marc Wilkens, Tom Brüske, Utz Welker, Volker Heinemann, Petra Zimmermann, Salvador Fernandez de la Maza, Dietrich Pfeiffer, Roland Tauber, Dorothea Thomas, Christos Moustakis

J Contemp Brachytherapy 2018; 10, 4: 297–305
Online publish date: 2018/08/31
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
To assess the effectiveness of low-dose-rate (LDR) brachytherapy in patients with localized prostate cancer and to compare the outcome with predictions from Kattan and Partin nomograms at 60 months after seed implantation.

Material and methods
One thousand, one hundred and eighty-seven patients with localized prostate cancer at low-, intermediate-, or high-risk of progression received LDR brachytherapy using iodine-125 seeds with curative intent, applied as monotherapy or in combination with external beam radiation therapy (EBRT), and/or androgen deprivation therapy (ADT). At 60 months after seed implantation, data of 1,064 patients (1,058 alive + 6 who died of prostate cancer) were analyzed for biochemical progression-free survival (bPFS) based on prostate-specific antigen (PSA) levels using the Phoenix definition. Five-year bPFS probabilities were determined for various risk group classifications (d’Amico, Mt. Sinai, MSKCC/Seattle, NCCN). Outcomes were also compared to patient-individualized nomogram predictions of 5-year bPFS (Kattan 2002) and probability of organ-confined disease (Kattan 2002, Partin 2007).

Overall, 93.3% (993/1,064) of the patients were free of biochemical progression within 5 years, while the average 5-year bPFS probability according to the Kattan nomogram was significantly lower (85%, p < 0.001). Outcomes were significantly better than Kattan nomogram predictions in the subgroup of patients with monotherapy as well as in patients additionally treated with EBRT. Comparison of the overall outcome with nomogram predictions for organ-confined disease (Kattan nomogram: 50%; Partin nomogram: 65%) revealed a significant probability of LDR brachytherapy to destroy periprostatic tumor spread (p < 0.001) in all risk group constellations, even in high-risk patients.

The results indicate high effectiveness of LDR brachytherapy in all risk groups, significantly better than predicted with the Kattan nomogram in most subgroups. The significant superiority of LDR brachytherapy compared to nomogram predictions of organ-confined disease suggests that LDR brachytherapy effectively controls both intra- and periprostatic disease.


brachytherapy, Kattan, nomogram prediction, Partin, periprostatic disease, prostate cancer, seeds

Blasko JC, Grimm PD, Sylsvester JE et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000; 57: 273-278.
Grimm P, Billiet I, Bostwick D et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 109 Suppl 1: 22-29.
Ragde H, Grado GL, Nadir B et al. Modern prostate brachytherapy. CA Cancer J Clin 2000; 50: 380-393.
Stone NN, Stock RG. 15-year cause specific and all-cause survival following brachytherapy for prostate cancer: negative impact of long-term hormonal therapy. J Urol 2014; 192: 754-759.
Sylvester JE, Grimm PD, Wong J et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 2011; 81: 376-381.
Zaorsky NG, Davis BJ, Nguyen PL et al. The evolution of brachytherapy for prostate cancer. Nat Rev Urol 2017; 14: 415-439.
Davis BJ, Horwitz EM, Lee WR et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012; 11: 6-19.
Leitlinienprogramm Onkologie. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 4.0 (Interdisciplinary German guidelines for diagnosis and therapy of prostate cancer, version 4.0). Available at: http://leitlinienprogramm-onkologie.de/Prostatakarzinom.58.0.html. 2016.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 3.2016. Available at: nccn.org/professionals/physician_gls/pdf/prostate.pdf. 2016.
Mottet N, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017; 71: 618-629.
Ash D, Flynn A, Battermann J et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000; 57: 315-321.
Morris WJ, Tyldesley S, Rodda S et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2017; 98: 275-285.
Trone JC, Espenel S, Rehailia-Blanchard A et al. Navigating the highlights of phase III trials: a watchful eye on evidence-based radiotherapy. Ann Oncol 2017; 28: 2691-2697.
Davis BJ, Pisansky TM, Wilson TM et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 1999; 85: 2630-2637.
Kattan MW, Scardino PT. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer 2002; 1: 90-96.
Makarov DV, Trock BJ, Humphreys EB et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-1101.
Basiri A, de la Rosette JJ, Tabatabaei S et al. Comparison of retropubic, laparoscopic and robotic radical prostatectomy: who is the winner? World J Urol 2018; 36: 609-621.
Inada M, Yokokawa M, Minami T et al. Dosimetry advantages of intraoperatively built custom-linked seeds compared with loose seeds in permanent prostate brachytherapy. J Contemp Brachytherapy 2017; 9: 410-417.
Salembier C, Lavagnini P, Nickers P et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007; 83: 3-10.
D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002; 52: 444-452.
Sylvester JE, Grimm PD, Blasko JC et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 2007; 67: 57-64.
Roach M 3rd, Hanks G, Thames H, Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-974.
Polo A, Salembier C, Venselaar J et al. Review of intraoperative imaging and planning techniques in permanent seed prostate brachytherapy. Radiother Oncol 2010; 94: 12-23.
Marshall RA, Buckstein M, Stone NN et al. Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-year experience at Mount Sinai Medical Center. Urol Oncol 2014; 32: 38.e31-37.
Taira AV, Merrick GS, Butler WM et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011; 79: 1336-1342.
Langley SEM, Soares R, Uribe J et al. Long-term oncological outcomes and toxicity in 597 men aged  60 years at time of low-dose-rate brachytherapy for localised prostate cancer. BJU Int 2018; 121: 38-45.
Kittel JA, Reddy CA, Smith KL et al. Long-Term Efficacy and Toxicity of Low-Dose-Rate (125)I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2015; 92: 884-893.
Cosset JM, Flam T, Thiounn N et al. Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the Paris Institut Curie/Cochin Hospital/Necker Hospital group on 809 patients. Int J Radiat Oncol Biol Phys 2008; 71: 1042-1048.
Yan W, Chen J, Zhou Y et al. Long-term outcome of early stage prostate cancer treated with brachytherapy analysis after a mean follow-up of 7 years. Springerplus 2014; 3: 357.
Ito K, Saito S, Yorozu A et al. Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival. Int J Clin Oncol 2018; DOI: 10.1007/s10147-10018-11309-10140.
Kaplan A, German L, Chen J et al. Validation and comparison of the two Kattan nomograms in patients with prostate cancer treated with (125) iodine brachytherapy. BJU Int 2012; 109: 1661-1665.
Shukla G, Sarkar A, Hanlon A et al. Biochemical control and toxicity for favorable- and intermediate-risk patients using real-time intraoperative inverse optimization prostate seed implant: Less is more! Brachytherapy 2017; 16: 490-496.
Okazaki E, Kuratsukuri K, Ishii K et al. Correlations of post-implant regional dosimetric parameters at 24 hours and one month, with clinical results of low-dose-rate brachytherapy for localized prostate cancer. J Contemp Brachytherapy 2017; 9: 499-507.
Spratt DE, Soni PD, McLaughlin PW et al. American Bra­chy­therapy Society Task Group Report: Combination of bra­chytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy 2017; 16: 1-12.
Giberti C, Chiono L, Gallo F et al. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol 2009; 27: 607-612.
Giberti C, Gallo F, Schenone M et al. Robotic prostatectomy versus brachytherapy for the treatment of low risk prostate cancer. Can J Urol 2017; 24: 8728-8733.
Pompe RS, Davis-Bondarenko H, Zaffuto E et al. Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. Prostate 2017; 77: 686-693.
Shilkrut M, Merrick GS, McLaughlin PW et al. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer 2013; 119: 681-690.
Bittner N, Merrick GS, Galbreath RW et al. Treatment outcomes with permanent brachytherapy in high-risk prostate cancer patients stratified into prognostic categories. Brachytherapy 2015; 14: 766-772.
Carpenter TJ, Forsythe K, Kao J et al. Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. Brachytherapy 2011; 10: 261-268.
Jackson MW, Amini A, Jones BL et al. Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer. Brachytherapy 2017; 16: 790-796.
Okamoto K, Wada A, Kohno N. High biologically effective dose radiation therapy using brachytherapy in combination with external beam radiotherapy for high-risk prostate cancer. J Contemp Brachytherapy 2017; 9: 1-6.
Dayes IS, Parpia S, Gilbert J et al. Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. Int J Radiat Oncol Biol Phys 2017; 99: 90-93.
Sathya JR, Davis IR, Julian JA et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005; 23: 1192-1199.
Hoskin PJ, Rojas AM, Bownes PJ et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012; 103: 217-222.
Pickles T, Morris WJ, Keyes M. High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy. Brachytherapy 2017; 16: 1101-1105.
Keyes M, Merrick G, Frank SJ et al. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy – a systematic literature review. Brachytherapy 2017; 16: 245-265.
Burchardt W, Skowronek J. Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer. J Contemp Brachytherapy 2018; 10: 1-9.
Martell K, Meyer T, Sia M et al. Parameters predicting for prostate specific antigen response rates at one year post low-dose-rate intraoperative prostate brachytherapy. J Contemp Brachytherapy 2017; 9: 99-105.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe